Vaxcyte, Inc. (PCVX) Stock Score, Valuation & Financial Research

Vaxcyte, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for PCVX

Vaxcyte, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 69.76. These figures are a research snapshot, not a buy or sell recommendation.

What Vaxcyte, Inc. does

Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infectious diseases. The company's leading vaccine candidate is VAX-24, an experimental 24-valent pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials, intended to address invasive pneumococcal disease and pneumonia. Beyond its flagship candidate, Vaxcyte is also advancing several other vaccine programs: VAX-XP, designed to offer protection against emergent bacterial strains and counter antimicrobial resistance; VAX-A1, a conjugate vaccine formulation aimed at Group A Streptococcus; and VAX-PG, a novel protein vaccine specifically developed to target the key pathogen responsible for periodontitis. The organization, which was initially established as SutroVax, Inc., officially rebranded as Vaxcyte, Inc. in May 2020. Founded in 2013, its corporate headquarters are situated in San Carlos, California.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Vaxcyte is a clinical-stage biotechnology company that has not yet generated revenue from product sales. Its business model is currently focused on research and development, clinical trials, and manufacturing readiness for its vaccine candidates, relying on capital raises to fund these activities until it can obtain regulatory approval and commercialize its products.

Products and services

  • The company is developing a pipeline of vaccine candidates, including VAX-24 and VAX-31, which are pneumococcal conjugate vaccine (PCV) candidates designed to prevent invasive pneumococcal disease and pneumonia.

Suppliers, materials and equipment

  • Lonza — Contract manufacturer providing production services for clinical and commercial-stage products. Source

Business relationships and partnerships

  • Lonza — A contract manufacturing partnership to secure capacity, technical expertise, and resources for the production of eCRM, polysaccharides, and drug substance for the company's PCV candidates. Source

Business strengths to evaluate

  • Proprietary XpressCF cell-free protein synthesis platform Source

Business risks and research considerations

  • Clinical-stage company with no history of commercial product sales or revenue Source
  • High dependency on the success of VAX-24 and VAX-31 clinical development Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

PCVX financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 69.76
Market capitalization:
10.07B (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -1.06B
Free cash flow:
USD -669.29M
Cash:
USD 183.19M
Total debt:
USD 115.45M
EPS:
USD -7.64

What stands out

  • Free cash flow is USD -669.29M, negative for the stored period.
  • The balance sheet shows USD 183.19M of cash versus USD 115.45M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a missing revenue history warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 67.75M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for PCVX

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can PCVX fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is PCVX likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for PCVX to reach sustainable profitability?
  • What does the current missing revenue history warning mean for the reliability or interpretation of PCVX's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-12.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research PCVX

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.